TY - JOUR T1 - Analysis of Mesencephalic Astrocyte-derived Neurotrophic Factor in Multiple Myeloma JF - Anticancer Research JO - Anticancer Res SP - 4305 LP - 4312 DO - 10.21873/anticanres.15235 VL - 41 IS - 9 AU - AMANDINE DERNONCOURT AU - CHLOE SAUZAY AU - JEAN SCHMIDT AU - CHRISTOPHE LOUANDRE AU - CATHY GOMILA AU - PIERRE DUHAUT AU - YVES-EDOUARD HERPE AU - ZUZANA SAIDAK AU - ANTOINE GALMICHE AU - VALERY SALLE Y1 - 2021/09/01 UR - http://ar.iiarjournals.org/content/41/9/4305.abstract N2 - Background/Aim: Multiple myeloma (MM) is characterized by high production of immunoglobulins resulting in a constant source of endoplasmic reticulum (ER)-stress. Mesencephalic astrocyte-derived neurotrophic factor (MANF) was identified as a possible circulating biomarker that could help in monitoring ER-stress mediated diseases. Materials and Methods: To assess the relevance of MANF in MM, we performed in silico and in vitro analysis in malignant cell lines including the myeloma cell line RPMI 8226. Serum MANF concentration was compared between healthy subjects (n=60), patients with MM (n=68), or those with monoclonal gammopathy of undetermined significance (MGUS) (n=73). Results: MANF mRNA expression was upregulated in the RPMI 8226 cell line, and higher secretion of MANF was measured in RPMI 8226 supernatant. Serum MANF levels were not significantly different between MM or MGUS patients and those in age- and sex-matched healthy controls. Conclusion: MANF was not validated as a biomarker of interest in MM patients. Its potential implication in myeloma pathogenesis should be investigated. ER -